Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy.

ABSTRACT: Lack of dystrophin causes muscle degeneration, which is exacerbated by chronic inflammation and reduced regenerative capacity of muscle stem cells in Duchenne Muscular Dystrophy (DMD). To date, glucocorticoids remain the gold standard for the treatment of DMD. These drugs are able to slow down the progression of the disease and increase lifespan by dampening the chronic and excessive inflammatory process; however, they also have numerous harmful side effects that hamper their therapeutic potential. Here, we investigated Resolvin-D2 as a new therapeutic alternative having the potential to target multiple key features contributing to the disease progression. Our in vitro findings showed that Resolvin-D2 promotes the switch of macrophages toward their anti-inflammatory phenotype and increases

SUBMITTER: Dort J 

PROVIDER: S-EPMC8556273 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature